A phase I/II study of REGN5678 (Anti-PSMAxCD28, a costimulatory bispecific antibody) with cemiplimab (anti–PD-1) in patients with metastatic castration-resistant prostate cancer.

Authors

• William Kelly

Publication/Presentation Date

3-2021

Volume

39

Issue

6

Published In/Presented At

DOI: 10.1200/JCO.2021.39.6_suppl.TPS174

Disciplines

Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods

Department(s)

Administration and Leadership

Document Type

Article